| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
idesa168
Elite |
18-Jan-2008 09:17
|
|
x 0
x 0 Alert Admin |
Double Good News! CE Approval & Trading Halt today in the downturn. If mkt recovers in the afternoon then Halt lifted, we will all laughing to the bank. I am leting go all my holding when starts trading. Mkt sentiment not so good lately. Cheers. |
| Useful To Me Not Useful To Me | |
|
wahlau_eh
Member |
18-Jan-2008 09:14
|
|
x 0
x 0 Alert Admin |
Hey, where is the announcement??? Cannot find it on SGX or even on the company website!!! Spoof??? |
| Useful To Me Not Useful To Me | |
|
|
|
|
huatah
Veteran |
18-Jan-2008 09:13
|
|
x 0
x 0 Alert Admin |
Bengster.. Congrats.. your efforts to add as a PR for BIG had paid off.. The potential is hugh.. Dun bother abt the TP indicator.. though all of us could take reference from investor analyzed figures.. CE Mark for BioMatrix obtained and the potential is far we could expect. With JNJ desperately finding smaller companies to compliment their shortfall.. de takeover px will subject to how desperate they r and how BIG viewed their offer.. Cheers to all of you who had believed bengster68 and who has been always supporting him. Chinese New Year coming.. and let's HUAT AHHHHHHHHHHHHHHHHHHH. dinola.. i reckon the lifting will b on 2nd half.. (guessing oni hor..) |
| Useful To Me Not Useful To Me | |
|
dinola
Member |
18-Jan-2008 09:06
|
|
x 0
x 0 Alert Admin |
Bendster, You save me! Thanks. Do you know when BIG resume trading? |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
18-Jan-2008 08:56
|
|
x 0
x 0 Alert Admin |
Just buy and hold. I try not to give TP in case short term holders below water start blaming me. This is a good company and undiscovered gem. If you have bought cheap, the best time to sell is......... almost never. Im happy with the progress of BIG and im confident BIG will become a global DES powerhouse. If people think at current prices BIG's share price is not sustainable, just wait a few more months and we will see. Im confident those that don't know the fundamentals of this company will be dead wrong. This company was too unappreciated and too grossly undervalued. Now market cap about US$0.7B. Conor was bought at US$1.4B (patent problems and lousy clinical results). Xience was bought at US$4.1B (no patent, good clinical results but late-thrombosis problems). BIG now has JWMS and solid patents and top class clinical recults (with zero late-thrombosis problem) in their pocket. Do you think BIG is overvalued now??? |
| Useful To Me Not Useful To Me | |
|
|
|
|
OkieDokie
Member |
18-Jan-2008 08:47
|
|
x 0
x 0 Alert Admin |
Finally.......Congrats to BIG and all vested ! We confirm this fact before BIG's SGX announcement. That's the power of internet ! BIOSENSORS receives CE Mark for its BioMatrix® DES with Biodegradable/BiolimusA9? technology January 17, 2008 ? Singapore ? Biosensors International Group, Ltd., today announced that it has received CE Mark approval for its BioMatrix® drug-eluting stent system, enabling commercialization of the product in most European countries, and in certain Asian, Middle Eastern and Latin American markets. Developed internally by Biosensors, BioMatrix is a unique drug-eluting stent (DES) system that combines a biodegradable PLA and the company?s proprietary limus drug, Biolimus A9®. ?We are very pleased to have received CE Mark for our BioMatrix DES system and will immediately implement our strategy to make this product available in approved markets. Our growth potential in these markets is very strong, thanks to the unique combination of a biodegradable PLA with an immunosuppressive drug. Positive clinical data position BioMatrix to be a potential break-through product for patients and physicians,? said Mr. Yoh-Chie Lu, Chairman and Chief Executive Officer of Biosensors. Prof. Eberhard Grube, Chief of Angiology and Cardiology at Siegburg Heart Center, Germany, and a principal investigator for the BioMatrix clinical trial program, commented, ?BioMatrix will provide a valuable alternative to the drug-eluting stents currently available. The results from the BioMatrix clinical trials have been consistently very positive and promising. The three-year follow-up data released at TCT 2007 continued to demonstrate BioMatrix?s superior results in terms of safety and clinical efficacy. The BioMatrix drug eluting stent has shown excellent procedural performance and outcome characteristics.? In addition to the positive results of its STEALTH I trial, Biosensors has ongoing and upcoming randomized clinical trials and post-market registries to monitor the long-term performance of the BioMatrix platform. ?We look forward to supporting physicians across Europe as we launch this exciting new product, and to helping them improve clinical outcomes for their patients,? said Jeffrey B. Jump, Managing Director of Biosensors Europe SA. Terumo Corporation also announced today that it has received CE Mark for its drug-eluting stent system, which incorporates Biosensors? DES technology. Under the terms of its licensing agreement with Biosensors, Terumo has the rights to sell its DES exclusively in Japan and non-exclusively outside Japan, excluding the United States. Biosensors has also licensed portions of its innovative DES technology to other companies developing specialized solutions for the treatment of long, complex lesions, multi-vessel disease and bifurcations. ?Today?s approval validates many years of effort toward developing the BioMatrix drug-eluting stent system. We would like to recognize the contributions of our employees and the collaborative efforts of our licensees in achieving this significant milestone,? concluded Mr. Lu. ? For product information about BioMatrix, please visit www.biomatrix.com ? For product sales inquiries, please email customer@biosensors.com ? For information about Biosensors, please visit our website: www.biosensors.com Note: You will be visiting sites outside of EuroPCRonline, we are not responsible for their contents. About BioMatrix® BioMatrix® offers the unique combination of an innovative anti-restenotic drug, Biolimus A9®, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability. Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately leaving in place a biocompatible stent surface. About Biosensors International Group, Ltd. Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional DES, bare-metal stents and open-heart surgery. It has three separate drug-eluting stent programs, BioMatrix®, Axxion?, and BioFreedom?, a completely polymer-free drug-eluting stent. Source: Biosensors International Group, Ltd. |
| Useful To Me Not Useful To Me | |
|
novena_33
Veteran |
18-Jan-2008 08:30
|
|
x 0
x 0 Alert Admin |
piss Bengster.....any revisie TP? dont know if they will resume trading today? |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
17-Jan-2008 22:23
|
|
x 0
x 0 Alert Admin |
BIG takeover season formally start liao..... JNJ's DES division is a bad shape and a takeover now can help JNJ capture back market from the over 50 CE standard countries plus China JW's potential for exports to 3rd world countries. Immediate contribution to JNJ's sales and profits. BIG is small but has the best DES technology and "firing at all cyclinders" after CE and JWMS in BIG's hand. Not an inducement to buy. Buy at your own risk. JUNE 18, 2007 Johnson & Johnson's Next Baby? J&J's selling lots of Band-Aids. But it could use an infusion of new drugs and devices from an acquisition such as Boston Scientific Johnson & Johnson (JNJ ) Chief Executive William Weldon has been yearning to get into the burgeoning market for devices that help defective hearts beat properly. In 2005, he was locked in a bidding war for Guidant, a struggling manufacturer of implantable cardiac devices (ICDs). Guidant, Weldon says, would have complemented J&J's own heart offerings, most notably stents?the tiny metal tubes that prop open blocked arteries. But when rival bidder Boston Scientific (BSX ) raised the ante to $27 billion in January, 2006, just as Guidant was facing a massive product recall, Weldon backed out of the fight. "It was disappointing," he says. "I guess you have to be pretty cold about it and say that [ICDs] would be a nice space to be in, but it has to be at a price that's going to return value to shareholders." Eighteen months later, Boston Scientific is struggling to turn around Guidant, raising an intriguing question: Could J&J swoop in and buy Boston Scientific? Stripping the math down to the simplest terms, it's not such an out-there idea. Boston Scientific's shares have lost 20% of their value in the last year, and the company now has a market cap of $24 billion?the highest J&J was willing to spend on Guidant. J&J ended up buying Pfizer's (PFE ) consumer-health business for $16.6 billion shortly after Guidant fell through. But Weldon asserts he could have done both deals, and few analysts would disagree. With $11 billion in free cash flow?an historic high?and little debt, J&J could easily pull off more multibillion-dollar acquisitions. MAKING UP FOR LOST STENTS A shopping spree may be the best remedy for J&J's growth challenges in its pharmaceutical and medical-devices divisions. A host of regulatory and marketing challenges could put pressure on J&J's stents and prescription drugs, which are far more lucrative than its over-the-counter pills and balms. "They have pressure on the franchises that are the most profitable and growth from the least profitable franchise," says Catherine Arnold, an analyst for Credit Suisse Group (CS ). Indeed, sales in the company's consumer division?home of iconic brands such as Johnson's Baby Powder, Band-Aid, and (thanks to the Pfizer deal) Listerine?grew 48%, to $3.5 billion, in the first quarter. The unit is expected to account for about a quarter of J&J's revenues this year, which are on track to hit $60 billion. But no matter how much Listerine J&J sells, it will need to shore up its drug and device units, which account for 75% of its total sales and 90% of its operating profit (see BusinessWeek, 4/23/07, "Under the Weather at J&J"). An acquisition could go a long way toward jump-starting J&J's medical-devices unit. Recent studies have sparked worries about "drug-eluting" stents that are coated with medicines designed to keep arteries clear. Some of the data suggests the stents may raise the risk of blood clots, and as a result, demand has flattened. Last year, J&J paid $1.4 billion for startup stent maker Conor MedSystems. Conor's next-generation stent promised to be a safe alternative to rival products, because it releases drugs in a precise, measured manner. But in May, a trial of Conor's most advanced stent failed and J&J pulled it from a handful of countries where it was already on the market. Some on Wall Street wonder if J&J blew a billion dollars. "J&J is becoming an afterthought in a market they were responsible for," snaps Frank Abella, CEO of Investment Partners Group , a portfolio management firm in Metuchen, N.J., which hasn't been recommending J&J stock lately. THE ACQUISITION STRATEGY J&J Chief Financial Officer Dominick Caruso says the company takes a long-term view of acquisitions that the Street doesn't always appreciate. J&J is famously rigorous when it comes to acquisitions. They could have waited six months for Conor's trial results to come in, Caruso says, but if the trial worked, the price tag would have gone up, making it a less attractive target. Furthermore, Caruso says, "We didn't buy this asset for the results of that clinical trial. We bought it because we thought it provided a novel drug-delivery platform that has other potential uses at J&J." Stent woes would argue against J&J buying Boston Scientific, which is the other major player in that market. J&J tends to stay away from troubled companies, choosing instead to swoop in when it's clear a company is firing on all cylinders. "J&J is comfortable paying a significant premium for businesses with a lot of certainty," notes Banc of America (BAC ) analyst Glenn Novarro . J&J's execs had no qualms placing a value on Pfizer's consumer business that was a staggering four times its annual sales. Both Caruso and Weldon admit they're still pining for a way into the $5 billion market for devices that regulate the delicate rhythm of the heart. But they're put off by how long it's taking for doctors to regain confidence in ICDs. "The market is recovering, but not as fast as we would have liked," Caruso says. OTHER CANDIDATES Consolidation in the devices space has left precious few acquisition candidates. Last year, there were rumblings that J&J might buy Medtronic (MDT ), a Minneapolis-based maker of ICDs and other devices. But with a market cap of $60 billion, it could be too big of a bite, even for J&J. Medtronic's neighbor and rival ICD maker, St. Paul-based St. Jude Medical (STJ ), has a market cap of $15 billion. Still, antitrust concerns could make it challenging for J&J to pick up any of these players. Neither Weldon nor Caruso will speculate on potential targets. In general, Caruso says, "Cardiovascular is a strong, attractive space for us. We're still interested. But it has to be at the right price." J&J's pharmaceutical division could use a growth infusion, too. Several of the company's top-selling drugs have suffered blows in recent months. The anemia drug Procrit brings in $3 billion in annual sales, but earlier this year the Food & Drug Administration added a warning to the labels of Procrit and competing drugs, indicating they might cause death if used at higher-than-recommended doses. The FDA is now weighing further restrictions on anemia drugs. What's worse, J&J is facing patent expirations on its schizophrenia drug Risperdal and its epilepsy treatment Topamax, which together account for $7 billion in annual sales. With few obvious blockbusters in the wings, J&J might need to acquire drugs that are close to hitting the market. In the past, J&J's tendency has been to partner with other companies rather than to buy them. It has a deal with Bayer HealthCare , for example, to co-develop an anti-clotting drug. But with free cash flow at an all-time high, analysts say they wouldn't be surprised if J&J goes shopping for small, innovative companies with promising drug candidates. BIG IS POSSIBLE, SMALL IS BETTER Even a big acquisition wouldn't be out of the question. On Mar. 19, Credit Suisse's Arnold released a report suggesting J&J could buy Bristol-Myers (BMY ), the New York drug giant that makes the anti-clotting drug Plavix. Bristol's strong pipeline, coupled with share weakness brought on by legal challenges, has turned the company into a hot acquisition target (see BusinessWeek, 2/26/07, "The Power of the Pipeline"). Antitrust concerns, however, could put a damper on a J&J/Bristol combination, she warns. As for Weldon, he says he's more likely to think small. "We prefer to go after smaller companies, so we can take our science, our people, and complement what they have," he says. "We prefer companies that have a lot of runway ahead of them." He may need a few more of those to keep J&J from stalling. |
| Useful To Me Not Useful To Me | |
|
|
|
|
investor
Senior |
17-Jan-2008 22:08
|
|
x 0
x 0 Alert Admin |
Got the news from Europcronline.com. |
| Useful To Me Not Useful To Me | |
|
Pwong1
Member |
17-Jan-2008 21:53
|
|
x 0
x 0 Alert Admin |
Although I am not vested in this but congratulations to all who invested in this. Good article in business times today |
| Useful To Me Not Useful To Me | |
|
cwwan1
Member |
17-Jan-2008 21:48
|
|
x 0
x 0 Alert Admin |
MR investor, thanks for the posting, Where u get this posting from? i cannot find in the terumo web page. |
| Useful To Me Not Useful To Me | |
|
gbleng
Member |
17-Jan-2008 21:47
|
|
x 0
x 0 Alert Admin |
I f Nobori gets CE then Biomatrix should also get it because they use the same technology and same drug... right bro beng??? |
| Useful To Me Not Useful To Me | |
|
|
|
|
novena_33
Veteran |
17-Jan-2008 21:42
|
|
x 0
x 0 Alert Admin |
so now halt 
... are they serving the main course ? 
|
| Useful To Me Not Useful To Me | |
|
singaporegal
Supreme |
17-Jan-2008 21:19
Yells: "Female TA nut" |
|
x 0
x 0 Alert Admin |
This is a VERY volatile counter so my TA technique may not be so accurate. TA charts looking generally good with Acc/Dist and Chaikin rising. The price is also hugging the upper bollinger band which is another good sign. Be wary though.... because I think this is a very speculative counter. |
| Useful To Me Not Useful To Me | |
|
cwwan1
Member |
17-Jan-2008 21:15
|
|
x 0
x 0 Alert Admin |
It is possible as biomatrix and noboric are the same stent!! BIO going to collect money liao! |
| Useful To Me Not Useful To Me | |
|
cwwan1
Member |
17-Jan-2008 21:08
|
|
x 0
x 0 Alert Admin |
YES!!!!Double happiness for BIO. |
| Useful To Me Not Useful To Me | |
|
investor
Senior |
17-Jan-2008 21:01
|
|
x 0
x 0 Alert Admin |
Managed to get this extract from another website.
For info only. Don't know if it is true.
TERUMO Receives CE Certificate for Nobori? Drug-Eluting Stent
January, 16, 2008 ? Tokyo, Japan, Leuven, Belgium ? Terumo Corporation, announced today that it has received CE certificate for the commercial sale of the Nobori? Drug-Eluting Coronary Stent System in European Economic Area. The Nobori? stent system is a truly new generation drug eluting stent (DES) with a bioresorbable polymer, offering best in class clinical results, excellent deliverability and strong patient safety profile. The company intends to launch the product shortly and to expand to more than 20 countries during the first quarter of fiscal year 08. Regulatory approval of the Nobori? stent was based on exceptional clinical data obtained in a comprehensive NOBORI clinical program. The program included NOBORI 1 with its two phases, NOBORI CORE and NOBORI Pharmacokinetics study. In randomized studies versus Taxus Express® and Taxus Libertè® the Nobori? stent proved its non-inferiority and even superiority in efficacy endpoints such as late loss, with an exceptionally low frequency of adverse cardiac events and no stent thrombosis up to 1 year in phase 1 and 9 months in phase 2. In NOBORI CORE, a comparative study versus Cypher® stent, Nobori? also showed excellent performance with very low rate of adverse cardiac events. The overall restenosis rate in all NOBORI trials was as low as 0.5% and no late stent thrombosis was recorded in any of the trials. Terumo plans additional clinical activities with the Nobori? stent as part of a comprehensive program to characterize the stent?s long-term safety and efficacy in a variety of patient populations. The program will enroll more than 5,000 patients in randomized trials and post-marketing registry in Europe, Asia, New Zealand and Africa. ?The Nobori? drug-eluting stent represents an extraordinary achievement of our research, development, manufacturing, clinical and regulatory people and adds an important product to our robust portfolio. The regulatory approval of the Nobori? stent in Europe and related activities in our home market demonstrate Terumo?s commitment to interventional cardiology,? said Yutaro Shintaku, Group President, Cardiac & Vascular Business, Terumo Corporation. ?Our sales and marketing people are fully trained and ready to take up the challenge of launching the Nobori? stent. With two excellent stent systems, Tsunami? BMS (bare metal stent) and Nobori? DES, Terumo will be able to offer safe and effective treatment options for broad range of patients with coronary artery disease?, said Hideo Arase, President and CEO of Terumo Europe N.V.. About Nobori? stent The Nobori? stent system utilizes Biolimus A9?, an analogue of sirolimus which is expected to reduce tissue proliferation and which is eluted from a bioresorbable polymer, poly-lactic acid. The stent delivery system applies Terumo?s proprietary hydrophilic coating which enhances deliverability and reduces arterial wall damage.
About Terumo Terumo is a global health care company dedicated to research, development, manufacturing and marketing of medical products and equipment, including pharmaceuticals, nutritional food supplement, blood bags, disposable medical devices, cardiovascular systems, vascular grafts, peritoneal dialysis, blood glucose monitoring system, medical electronic, and digital thermometers. The main company vision is to contribute to the society through health care using its unique technology which makes medical treatment kinder and gentler.
Terumo employs more than 12.000 people and its products are available in over 150 countries world-wide. Biolimus A9? and technology of its elution from bioresorbable polymer (poly-lactic acid) is a proprietary of Biosensors International with whom Terumo, in the year 2003, signed a licensing agreement for the development and marketing of drug eluting stent. Clinical results of Nobori? stent were also used for the regulatory approval of Biosensor?s drug eluting stent. For more information: Nori Kunimoto nobori@terumo-europe.com |
| Useful To Me Not Useful To Me | |
|
cwwan1
Member |
17-Jan-2008 20:49
|
|
x 0
x 0 Alert Admin |
I predict this week CE comes out....quite zhun :)). Actually u all knows already from bengster mail, me just remind u all... BIG CHEONG ARRRRRRH |
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
17-Jan-2008 19:57
|
|
x 0
x 0 Alert Admin |
ok, i will checked with my broker. anyway thanks for checking for me, i have thought i missed it and just forget abt it.. just realised that i could have overtraded my limit as i entered other positions today and i miscalculated my margin hence my order was rejected by the system but i didnt see it. my fault, as i rush to watch TV prog after i key the trade, should have check properly and not assume. if i have checked, i may have entered a smaller lot the margin level for jiutian and the etf STI is not as high as i thought. i better find out the exact margin level.. conclusion: dun ass-ume! |
| Useful To Me Not Useful To Me | |
|
EastWind
Member |
17-Jan-2008 19:53
|
|
x 0
x 0 Alert Admin |
cashiertan , I sincerely hope that you would have gotten it at the closing matching price. I am sure everyone here also hopes that everyone here will huat together (assuming that it is good news, of course). |
| Useful To Me Not Useful To Me | |